CatalystMarker
← board

TLRY

distress 3/10 · well-funded / low risk
$4.10-1%today-80% from 52w high
tilray.com2,842 employeesLeamington, ONDrug Manufacturers - Specialty & Generic
Revenue
$634M
Liquidity
$228M
Runway
2.4 yrs
Shares 1y
-89%

Price & events

-55.1% over 6M
$4.10$6.62$9.13Jan 26Apr 26Jul 2642.8Mdilution: 424B7 offering (2026-04-21)dilution: 424B5 offering (2026-04-15)financing: 8-K private_placement (2026-06-30)financing: 8-K private_placement (2026-06-09)financing: 8-K material_agreement (2026-04-15)financing: 8-K private_placement (2026-04-15)financing: 8-K material_agreement (2026-03-02)rating: TD Cowen: Buy (2026-07-14)rating: Roth Capital: Neutral → Buy (2026-04-02)rating: TD Cowen: Buy (2026-03-30)
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
-5.7%
1W
-11.1%
1M
-40.9%
3M
-54.7%
6M
-44.6%
1Y
-78.3%
2Y
-97.0%
5Y
-95.4%
All

Overview

Market Cap
$477.85M
Volume
307.81K
52 Week Range
$4.10 – $21.00
Total Shares
116.55M
Float Shares
444.06M
Short %
14.52%
% Held by Insiders
0.71%
% Held by Institutions
9.38%
RVOL
0.09x
Beta
1.90

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 2

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 116,548,663 · 3 offerings/1y · 3 PIPEs
  • 2026-06-308-Kprivate_placement
  • 2026-06-098-Kprivate_placement
  • 2026-04-21424B7offering
  • 2026-04-158-Kprivate_placement
  • 2026-04-158-Kmaterial_agreement
  • 2026-04-15424B5offering
  • 2026-03-028-Kmaterial_agreement
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

buy · target $9 (+127% upside) · 8 analysts
  • 2026-07-14TD CowenBuy
  • 2026-04-02Roth CapitalNeutral → Buy
  • 2026-03-30TD CowenBuy
  • 2026-01-20Roth CapitalNeutral
  • 2025-08-25JefferiesBuy
  • 2025-07-29Zelman & AssocNeutral

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.